MEI Pharma (NASDAQ:MEIP) on Monday said it would cut its workforce by about 30% and refocus its clinical development on two earlier assets. The actions come after the company and Japan's Kyowa Kirin (OTCPK:KYKOF) ended the development of cancer treatment zandelisib out of Japan. The company will streamline its organization towards the development of voruciclib and ME-344. "MEI expects existing cash sufficient to fund through clinical data milestones for voruciclib and ME-344," the company said in a statement. Moreover, MEIP said it had engaged Torreya Partners as a financial advisor to help explore additional strategic opportunities.